Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

TCRXTScan Therapeutics, Inc.

Nasdaq · CIK 0001783328
Filer categoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Entity typeoperating
SIC2836 Biological Products, (No Diagnostic Substances)
FY end1231
XBRL facts190

Identity from submissions API

NameTScan Therapeutics, Inc.
CIK0001783328
TickersTCRX
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SIC2836 Biological Products, (No Diagnostic Substances)
EIN825282075
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone857-399-9500
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • None listed.
Business address
830 WINTER STREET
WALTHAM
MA
02451
MA
Mailing address
830 WINTER STREET
WALTHAM
MA
02451
MA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

336 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-12 10-Q 10-Q 0001193125-26-456919 001-40603 261543155 34 7827264 1 1
2026-11-12 8-K 8-K 2.02,9.01 0001193125-26-456865 001-40603 261543030 34 411234 1 1
2026-10-26 DEF 14A DEF 14A 0001193125-26-431045 001-40603 261483587 34 610358
2026-10-16 PRE 14A PRE 14A 0001193125-26-424240 001-40603 261466848 34 600642
2026-10-16 8-K 8-K 5.02 0001193125-26-424198 001-40603 261466676 34 138546 1 1
2026-10-02 4 4 0001193125-26-412521 5004
2026-10-02 4 4 0001193125-26-412518 5034
2026-09-30 8-K 8-K 5.02 0001193125-26-409199 001-40603 261427813 34 140916 1 1
2026-09-25 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0002063423-26-000002 005-92700 261410516 34 15139
2026-09-11 8-K 8-K 5.02 0001193125-26-388631 001-40603 261372713 34 143600 1 1
2026-09-02 8-K 8-K 2.05,3.01,5.02,7.01,8.01,9.01 0001193125-26-379343 001-40603 261352639 34 2714969 1 1
2026-08-18 8-K 8-K 1.02 0001193125-26-355664 001-40603 261291731 34 141042 1 1
2026-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000902664-26-003526 005-92700 261282728 34 10608
2026-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000921895-26-002183 005-92700 261282118 34 25556
2026-08-12 10-Q 10-Q 0001193125-26-345749 001-40603 261265328 34 7761071 1 1
2026-08-12 8-K 8-K 2.02,9.01 0001193125-26-345732 001-40603 261265304 34 430637 1 1
2026-06-22 8-K 8-K 7.01,8.01,9.01 0001193125-26-276693 001-40603 261104887 34 7419514 1 1
2026-05-22 4 4 0001193125-26-236870 22565
2026-05-22 8-K 8-K 5.03,5.07,9.01 0001193125-26-236862 001-40603 261013699 34 170307 1 1
2026-05-22 4 4 0001193125-26-236855 5411
2026-05-22 4 4 0001193125-26-236854 5411
2026-05-22 4 4 0001193125-26-236848 5404
2026-05-22 4 4 0001193125-26-236844 5398
2026-05-22 4 4 0001193125-26-236841 5401
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000921895-26-001399 005-92700 26987540 34 25388
2026-05-06 10-Q 10-Q 0001193125-26-207572 001-40603 26945823 34 6701513 1 1
2026-05-06 8-K 8-K 2.02,9.01 0001193125-26-207549 001-40603 26945797 34 442150 1 1
2026-04-17 ARS ARS 0001193125-26-160310 001-40603 26869398 34 4562301
2026-04-17 DEF 14A DEF 14A 0001193125-26-160304 001-40603 26869394 34 849888 1 1
2026-04-07 PRE 14A PRE 14A 0001193125-26-145614 001-40603 26845331 34 850119 1 1
2026-04-02 8-K 8-K 5.02 0001193125-26-138973 001-40603 26830624 34 137843 1 1
2026-03-04 S-8 S-8 0001193125-26-089915 333-293989 26718865 33 184036 1 1
2026-03-04 10-K 10-K 0001193125-26-089884 001-40603 26718855 34 15368557 1 1
2026-03-04 8-K 8-K 2.02,9.01 0001193125-26-089871 001-40603 26718841 34 394992 1 1
2026-01-22 4 4 0001193125-26-019729 5368
2026-01-22 4 4 0001193125-26-019723 20576
2026-01-22 4 4 0001193125-26-019702 5478
2026-01-22 4 4 0001193125-26-019697 5409
2026-01-22 4 4 0001193125-26-019674 19868
2026-01-12 8-K 8-K 7.01,9.01 0001193125-26-009771 001-40603 26524667 34 4515454 1 1
2025-12-23 4 xslF345X05/ownership.xml 0000902664-25-005396 11729
2025-11-26 8-K 8-K 5.02 0001193125-25-300538 001-40603 251530428 34 142249 1 1
2025-11-12 10-Q 10-Q 0001193125-25-275933 001-40603 251468850 34 7629742 1 1
2025-11-12 8-K 8-K 2.02,9.01 0001193125-25-275889 001-40603 251468774 34 367473 1 1
2025-11-03 8-K 8-K 2.05,7.01,8.01,9.01 0001193125-25-261612 001-40603 251442035 34 784579 1 1
2025-09-09 8-K 8-K 7.01,9.01 0001193125-25-198768 001-40603 251301631 34 15231326 1 1
2025-08-22 3 3 0001193125-25-186427 28289
2025-08-20 8-K 8-K 5.02 0001193125-25-184083 001-40603 251236898 34 140230 1 1
2025-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-003579 005-92700 251214256 34 10330
2025-08-12 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-003515 005-92700 251204590 34 13007
2025-08-12 10-Q 10-Q 0000950170-25-106919 001-40603 251204029 34 7624697 1 1
2025-08-12 8-K 8-K 2.02,9.01 0000950170-25-106915 001-40603 251204008 34 424908 1 1
2025-07-16 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0002052113-25-002518 005-92700 251128494 34 10739
2025-07-02 4 4 0000950170-25-093232 22069
2025-07-02 4 4 0000950170-25-093058 19246
2025-07-02 4 4 0000950170-25-093057 5270
2025-07-02 4 4 0000950170-25-093047 5273
2025-07-02 4 4 0000950170-25-093021 19240
2025-07-02 4 4 0000950170-25-093020 19398
2025-07-02 8-K 8-K 5.07 0001193125-25-154336 001-40603 251098311 34 144167 1 1
2025-05-21 4 xslF345X05/ownership.xml 0000902664-25-002511 8948
2025-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000921895-25-001553 005-92700 25954481 34 25530
2025-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000935836-25-000367 005-92700 25951413 34 15891
2025-05-14 ARS ARS 0001193125-25-119385 001-40603 25942623 34 2256129
2025-05-14 DEFA14A DEFA14A 0001193125-25-119381 001-40603 25942600 34 629653
2025-05-14 DEF 14A DEF 14A 0001193125-25-119378 001-40603 25942591 34 1271921 1 1
2025-05-06 10-Q 10-Q 0000950170-25-063968 001-40603 25915245 34 6598910 1 1
2025-05-06 8-K 8-K 2.02,9.01 0000950170-25-063959 001-40603 25915218 34 443831 1 1
2025-04-24 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0002052113-25-001561 005-92700 25863910 34 10744
2025-03-14 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-25-000693 333-285570 25742156 33 1729
2025-03-12 CORRESP filename1.htm 0001193125-25-052682 5983
2025-03-11 UPLOAD filename1.pdf 0000000000-25-002674 333-285570 40044
2025-03-05 S-8 S-8 0001193125-25-047221 333-285571 25711574 33 70023
2025-03-05 S-3 S-3 0001193125-25-047159 333-285570 25711526 33 994807
2025-03-05 10-K 10-K 0000950170-25-033077 001-40603 25708868 34 20122055 1 1
2025-03-05 8-K 8-K 2.02,9.01 0000950170-25-033071 001-40603 25708814 34 489735 1 1
2025-02-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000905148-25-000661 005-92700 25629819 34 15504
2025-02-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-000979 005-92700 25623695 34 10392
2025-02-12 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-000872 005-92700 25612661 34 14285
2025-02-11 4 4 0000950170-25-018131 7723
2025-02-11 4 4 0000950170-25-018130 5386
2025-02-11 4 4 0000950170-25-018125 7674
2025-02-11 4 4 0000950170-25-018120 5299
2025-02-11 4 4 0000950170-25-018119 5361
2024-12-30 4 xslF345X05/ownership.xml 0000902664-24-007064 8668
2024-12-26 8-K 8-K 1.01,8.01,9.01 0001193125-24-284671 001-40603 241576188 34 422420 1 1
2024-12-26 424B5 424B5 0001193125-24-284669 333-268260 241576084 33 683242
2024-12-23 8-K 8-K 1.01,1.02,2.03,7.01,9.01 0001193125-24-283673 001-40603 241569873 34 561586 1 1
2024-12-16 4 xslF345X05/ownership.xml 0000902664-24-006934 9979
2024-12-10 8-K 8-K 7.01,8.01,9.01 0001193125-24-273985 001-40603 241537185 34 5626328 1 1
2024-11-21 8-K FORM 8-K 3.02 0000950142-24-002817 001-40603 241482217 34 197744 1 1
2024-11-19 4 xslF345X05/ownership.xml 0000902664-24-006718 7783
2024-11-14 SC 13G/A AMENDMENT NO. 1 TO SCHEDULE 13G 0000921895-24-002738 005-92700 241463529 34 278342
2024-11-14 SC 13G/A SC 13G/A 0001140361-24-046894 005-92700 241461900 34 122076
2024-11-14 SC 13G/A cormorant-tcrx093024a1.htm 0001172661-24-005052 005-92700 241460762 34 87645
2024-11-12 10-Q 10-Q 0000950170-24-124575 001-40603 241443307 34 6069548 1 1
2024-11-12 8-K 8-K 2.02,9.01 0000950170-24-124558 001-40603 241443245 34 346193 1 1
2024-11-08 SC 13G us89854m1018_110824.txt 0002012383-24-003685 005-92700 241439799 34 13692
2024-11-01 8-K 8-K 1.01,9.01 0001193125-24-249124 001-40603 241417007 34 149716 1 1
2024-10-21 SC 13G us89854m1018_102124.txt 0002012383-24-000954 005-92700 241383590 34 13680
2024-09-24 4 4 0000950170-24-109133 5541
2024-08-27 4 4 0000950170-24-101166 6972
2024-08-27 4 4 0000950170-24-101161 20455
2024-08-23 144 xsl144X01/primary_doc.xml 0001972362-24-001224 001-40603 241237390 33 4701
2024-08-12 10-Q 10-Q 0000950170-24-095066 001-40603 241194751 34 6064200 1 1
2024-08-12 8-K 8-K 2.02,9.01 0000950170-24-095063 001-40603 241194726 34 336136 1 1
2024-06-14 4 4 0000950170-24-073696 5280
2024-06-14 4 4 0000950170-24-073695 5247
2024-06-14 4 4 0000950170-24-073694 5268
2024-06-14 4 4 0000950170-24-073693 5254
2024-06-14 4 4 0000950170-24-073692 7606
2024-06-14 3 3 0000950170-24-073670 16839
2024-06-14 4 4 0000950170-24-073658 22076
2024-06-14 S-8 FORM S-8 0001193125-24-161589 333-280212 241044709 33 69763
2024-06-14 8-K 8-K 5.02,5.07,9.01 0001193125-24-161151 001-40603 241043137 34 326109 1 1
2024-05-13 10-Q 10-Q 0000950170-24-058198 001-40603 24936878 34 5513803 1 1
2024-05-13 8-K 8-K 2.02,9.01 0000950170-24-058194 001-40603 24936858 34 343285 1 1
2024-05-03 4 4 0000950170-24-052872 5362
2024-05-02 3 3 0000950170-24-052061 13387
2024-04-30 ARS ARS 0001193125-24-125141 001-40603 24897410 34 1796940
2024-04-30 DEFA14A DEFA14A 0001193125-24-125079 001-40603 24897275 34 742906
2024-04-30 DEF 14A DEF 14A 0001193125-24-125066 001-40603 24897177 34 924739
2024-04-29 SC 13G sc13g.htm 0000929638-24-001648 005-92700 24890496 34 99518
2024-04-23 SC 13D/A SC 13D/A 0001104659-24-050607 005-92700 24865144 34 99253
2024-04-23 4 4 0000950170-24-046916 20897
2024-04-23 4 xslF345X05/ownership.xml 0000902664-24-003030 8642
2024-04-18 424B5 424B5 0001193125-24-099491 333-277699 24852674 33 652027
2024-04-17 8-K 8-K 1.01,2.02,8.01,9.01 0001193125-24-098509 001-40603 24849333 34 614653 1 1
2024-04-17 FWP FWP 0001193125-24-098504 333-277699 24849330 34 14878
2024-04-16 424B5 424B5 0001193125-24-097937 333-277699 24848751 33 649627
2024-04-16 8-K 8-K 7.01,8.01,9.01 0001193125-24-097764 001-40603 24848018 34 17259142 1 1
2024-04-12 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2024-04-12 09:00:00 9999999995-24-000956 333-277699 24843000 33 1729
2024-04-10 CORRESP filename1.htm 0001193125-24-091404 6249
2024-04-10 10-K/A 10-K/A 0001193125-24-091386 001-40603 24834256 34 621528 1 1
2024-04-08 8-K 8-K 8.01,9.01 0001193125-24-089164 001-40603 24828226 34 171830 1 1
2024-03-07 UPLOAD filename1.pdf 0000000000-24-002553 333-277699 40278
2024-03-06 S-3 S-3 0001193125-24-060718 333-277699 24725978 33 1038536
2024-03-06 S-8 S-8 0001193125-24-060705 333-277695 24725865 33 70876
2024-03-06 10-K 10-K 0000950170-24-026875 001-40603 24724376 34 12159361 1 1
2024-03-06 8-K 8-K 2.02,9.01 0000950170-24-026868 001-40603 24724361 34 364838 1 1
2024-02-14 SC 13G/A SC 13G/A 0001140361-24-008030 005-92700 24639635 34 118750
2024-02-09 SC 13G/A SC 13G/A 0001104659-24-012937 005-92700 24614869 34 189423
2024-02-08 SC 13G/A SC 13G/A 0001104659-24-011824 005-92700 24606694 34 105363
2024-02-07 SC 13G/A TSCAN THERAPEUTICS, INC. 0000902664-24-001174 005-92700 24602194 34 94366
2024-02-02 4 4 0000950170-24-010522 5323
2024-02-02 3 3 0000950170-24-010500 14149
2024-01-29 8-K 8-K 5.02,9.01 0001193125-24-017379 001-40603 24570080 34 178900 1 1
2023-12-21 4 4 0000950170-23-072291 7402
2023-12-18 4 4 0000950170-23-071208 5541
2023-12-11 8-K 8-K 7.01,8.01,9.01 0001193125-23-292080 001-40603 231476949 34 3505208 1 1
2023-12-08 4 4 0000950170-23-068925 5201
2023-12-08 3 3 0000950170-23-068924 15483
2023-12-07 8-K 8-K 5.02,9.01 0001193125-23-290309 001-40603 231471066 34 170776 1 1
2023-11-09 10-Q 10-Q 0000950170-23-061533 001-40603 231390068 34 6336602 1 1
2023-11-09 8-K 8-K 2.02,9.01 0000950170-23-061525 001-40603 231390043 34 362579 1 1
2023-08-10 10-Q 10-Q 0000950170-23-040961 001-40603 231157185 34 7433975 1 1
2023-08-10 8-K 8-K 2.02,9.01 0000950170-23-040954 001-40603 231157167 34 387747 1 1
2023-07-25 8-K 8-K 5.02,9.01 0001193125-23-192484 001-40603 231106118 34 150056 1 1
2023-07-24 4 4 0000950170-23-034156 5255
2023-07-24 3 3 0000950170-23-034147 8072
2023-06-29 8-K 8-K 5.02,7.01,9.01 0001193125-23-178075 001-40603 231054398 34 173189 1 1
2023-06-16 S-8 S-8 0001193125-23-169052 333-272733 231021822 33 60859
2023-06-16 8-K 8-K 5.02,5.07,9.01 0001193125-23-168118 001-40603 231018658 34 172742 1 1
2023-06-15 4 FORM 4 SUBMISSION 0000899243-23-015646 5420
2023-06-15 4 FORM 4 SUBMISSION 0000899243-23-015644 6043
2023-06-15 4 FORM 4 SUBMISSION 0000899243-23-015642 5393
2023-06-15 4 FORM 4 SUBMISSION 0000899243-23-015640 5400
2023-06-15 4 FORM 4 SUBMISSION 0000899243-23-015639 5530
2023-06-15 4 FORM 4 SUBMISSION 0000899243-23-015636 6050
2023-06-15 4 FORM 4 SUBMISSION 0000899243-23-015635 6047
2023-06-15 4 FORM 4 SUBMISSION 0000899243-23-015632 6046
2023-06-15 4 FORM 4 SUBMISSION 0001209191-23-037371 22147
2023-06-12 SC 13G TSCAN THERAPEUTICS, INC. 0000902664-23-003533 005-92700 231008518 34 106899
2023-06-08 SC 13G/A us89854m1018_060623.txt 0001306550-23-009221 005-92700 231001419 34 12229
2023-06-06 4 FORM 4 SUBMISSION 0000899243-23-014618 6390
2023-06-05 SC 13G SCHEDULE 13G 0000921895-23-001429 005-92700 23993228 34 288522
2023-06-05 SC 13G tscan.htm 0000935836-23-000439 005-92700 23992546 34 47323
2023-06-05 3 xslF345X02/ownership.xml 0000935836-23-000438 5046
2023-06-02 4 xslF345X04/ownership.xml 0000902664-23-003407 10466
2023-06-02 3 xslF345X02/ownership.xml 0000902664-23-003406 6211
2023-06-02 SC 13G TSCAN THERAPEUTICS, INC.. 0000902664-23-003397 005-92700 23989844 34 68702
2023-06-02 SC 13D/A SC 13D/A 0001104659-23-067540 005-92700 23988681 34 91734
2023-06-02 DEFA14A DEFA14A 0001193125-23-159826 001-40603 23988671 34 596151
2023-06-02 4 FORM 4 SUBMISSION 0001209191-23-033647 21099
2023-05-31 8-K 8-K 1.01,8.01,9.01 0001193125-23-157307 001-40603 23979030 34 572697 1 1
2023-05-31 8-K 8-K 5.02,7.01,9.01 0001193125-23-157286 001-40603 23978995 34 172745 1 1
2023-05-30 424B5 424B5 0001193125-23-155650 333-268260 23971124 33 685039
2023-05-26 FWP FWP 0001193125-23-154726 333-268260 23962989 34 15093
2023-05-25 424B5 424B5 0001193125-23-154339 333-268260 23961768 33 704239
2023-05-17 8-K 8-K 8.01,9.01 0001193125-23-146584 001-40603 23929686 34 188278 1 1
2023-05-16 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2023-05-16 16:00:00 9999999995-23-001449 333-268261 23929558 33 1680
2023-05-16 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2023-05-16 16:00:00 9999999995-23-001448 333-268260 23929557 33 1680
2023-05-16 8-K 8-K 8.01,9.01 0001193125-23-146203 001-40603 23928744 34 390588 1 1
2023-05-16 424B5 424B5 0001193125-23-146200 333-268260 23928727 33 584012
2023-05-16 AW AW 0001193125-23-145915 333-268260 23926536 NE 7303
2023-05-16 S-3/A S-3/A 0001193125-23-145297 333-268261 23925036 33 62441
2023-05-16 S-3/A S-3/A 0001193125-23-145261 333-268260 23924845 33 62441
2023-05-16 S-3/A S-3/A 0001193125-23-145259 333-268260 23924824 33 65032
2023-05-15 CORRESP filename1.htm 0001193125-23-145273 5951
2023-05-15 CORRESP filename1.htm 0001193125-23-145270 5951
2023-05-15 144 xsl144X01/primary_doc.xml 0001949846-23-000080 001-40603 23923500 33 5125
2023-05-10 CORRESP filename1.htm 0001193125-23-140850 5815
2023-05-10 CORRESP filename1.htm 0001193125-23-140844 5815
2023-05-10 10-Q 10-Q 0000950170-23-020087 001-40603 23904347 34 5664640 1 1
2023-05-10 8-K 8-K 2.02,9.01 0000950170-23-020082 001-40603 23904323 34 397768 1 1
2023-05-09 8-K 8-K 1.01,7.01,9.01 0001193125-23-139057 001-40603 23900265 34 203075 1 1
2023-04-25 ARS ARS 0001193125-23-114191 001-40603 23841802 34 14982893
2023-04-25 DEFA14A DEFA14A 0001193125-23-114151 001-40603 23841775 34 855745
2023-04-25 DEF 14A DEF 14A 0001193125-23-114116 001-40603 23841759 34 807382
2023-04-10 4 FORM 4 SUBMISSION 0000899243-23-010999 5358
2023-04-10 3 FORM 3 SUBMISSION 0000899243-23-010996 4691
2023-04-10 8-K 8-K 5.02,9.01 0001193125-23-095838 001-40603 23809721 34 180802 1 1
2023-03-31 8-K 8-K 5.02,7.01,9.01 0001193125-23-086922 001-40603 23783518 34 183753 1 1
2023-03-08 S-8 S-8 0001193125-23-063834 333-270343 23714889 33 66890
2023-03-08 10-K 10-K 0000950170-23-006589 001-40603 23714875 34 13719596 1 1
2023-03-08 8-K 8-K 2.02,9.01 0000950170-23-006586 001-40603 23714862 34 457343 1 1
2023-02-14 SC 13G/A TSCAN THERAPEUTICS, INC. 0000902664-23-001811 005-92700 23629295 34 46882
2023-02-06 4 FORM 4 SUBMISSION 0000899243-23-004063 5446
2023-02-06 4 FORM 4 SUBMISSION 0000899243-23-004062 5443
2023-02-06 4 FORM 4 SUBMISSION 0000899243-23-004064 5418
2023-02-06 4 FORM 4 SUBMISSION 0000899243-23-004061 5413
2023-02-03 SC 13G/A us89854m1018_020323.txt 0001306550-23-007802 005-92700 23586345 34 12949
2023-01-23 8-K 8-K 8.01,9.01 0001193125-23-012556 001-40603 23542500 34 174184 1 1
2022-12-29 4 FORM 4 SUBMISSION 0000899243-22-039506 6842
2022-11-15 UPLOAD filename1.pdf 0000000000-22-012378 40223
2022-11-15 UPLOAD filename1.pdf 0000000000-22-012377 40227
2022-11-09 S-3 S-3 0001193125-22-280728 333-268261 221370703 33 355865
2022-11-09 S-3 S-3 0001193125-22-280725 333-268260 221370701 33 1062336
2022-11-09 10-Q 10-Q 0000950170-22-023507 001-40603 221370640 34 6679449 1 1
2022-11-09 8-K 8-K 2.02,9.01 0000950170-22-023503 001-40603 221370621 34 484986 1 1
2022-09-30 SC 13G SC 13G 0001140361-22-035533 005-92700 221285003 34 117075
2022-09-12 8-K 8-K 1.01,2.03,7.01,9.01 0001193125-22-242437 001-40603 221237391 34 961579 1 1
2022-08-15 SC 13G/A SC 13G/A 0001104659-22-091307 005-92700 221166644 34 79850
2022-08-10 10-Q 10-Q 0000950170-22-016263 001-40603 221150443 34 5775081 1 1
2022-08-10 8-K 8-K 2.02,9.01 0000950170-22-016253 001-40603 221150381 34 358882 1 1
2022-07-27 4 FORM 4 SUBMISSION 0000899243-22-026849 5443
2022-07-27 4 FORM 4 SUBMISSION 0000899243-22-026848 5425
2022-07-27 4 FORM 4 SUBMISSION 0000899243-22-026847 5416
2022-07-27 4 FORM 4 SUBMISSION 0000899243-22-026846 5423
2022-07-27 4 FORM 4 SUBMISSION 0000899243-22-026844 5444
2022-07-07 4 FORM 4 SUBMISSION 0000899243-22-025626 5450
2022-07-07 3 FORM 3 SUBMISSION 0000899243-22-025624 2901
2022-07-07 8-K 8-K 5.02 0001193125-22-189000 001-40603 221070632 34 147826 1 1
2022-06-03 4 FORM 4 SUBMISSION 0001209191-22-034093 17142
2022-06-03 4 FORM 4 SUBMISSION 0000899243-22-020963 5356
2022-06-03 4 FORM 4 SUBMISSION 0000899243-22-020964 5383
2022-06-03 4 FORM 4 SUBMISSION 0000899243-22-020965 5363
2022-06-03 4 FORM 4 SUBMISSION 0000899243-22-020961 5354
2022-06-03 8-K 8-K 5.02,5.07 0001193125-22-167299 001-40603 22994269 34 151919 1 1
2022-05-31 8-K 8-K 8.01,9.01 0001193125-22-163006 001-40603 22980421 34 170563 1 1
2022-05-20 4 FORM 4 SUBMISSION 0000899243-22-019018 7132
2022-05-12 SC 13D/A SC 13D/A 0001104659-22-059502 005-92700 22918587 34 91321
2022-05-12 4 FORM 4 SUBMISSION 0001209191-22-028579 30531
2022-05-12 10-Q 10-Q 0000950170-22-009472 001-40603 22915772 34 5247640 1 1
2022-05-09 8-K 8-K 2.02,9.01 0000950170-22-008234 001-40603 22903219 34 327356 1 1
2022-04-21 DEFA14A DEFA14A 0001193125-22-112145 001-40603 22839717 34 577866
2022-04-21 DEF 14A DEF 14A 0001193125-22-112138 001-40603 22839700 34 787347
2022-03-28 4 FORM 4 SUBMISSION 0000899243-22-012476 5061
2022-03-09 S-8 S-8 0001193125-22-069921 333-263380 22723933 33 62122
2022-03-09 10-K 10-K 0000950170-22-003175 001-40603 22723914 34 12973005 1 1
2022-03-09 8-K 8-K 2.02,9.01 0001193125-22-069875 001-40603 22723894 34 208374 1 1
2022-02-14 SC 13G SC 13G 0001193125-22-042256 005-92700 22635079 34 102137
2022-02-14 SC 13G p22-0616sc13g.htm 0000902664-22-001707 005-92700 22631219 34 43673
2022-02-14 SC 13G SC 13G 0001193125-22-040482 005-92700 22627470 34 213241
2022-02-14 SC 13G SC 13G 0001104659-22-021924 005-92700 22626299 34 93214
2022-02-10 SC 13G SC 13G 0001193125-22-034689 005-92700 22615436 34 79603
2022-02-04 SC 13G us89854m1018_020422.txt 0000834237-22-007356 005-92700 22593610 34 12940
2022-01-24 8-K 8-K 8.01,9.01 0001193125-22-015468 001-40603 22547550 34 168649 1 1
2022-01-20 4 FORM 4 SUBMISSION 0000899243-22-002654 5427
2022-01-20 4 FORM 4 SUBMISSION 0000899243-22-002651 5420
2022-01-20 4 FORM 4 SUBMISSION 0000899243-22-002650 5425
2022-01-20 4 FORM 4 SUBMISSION 0000899243-22-002647 5445
2022-01-20 4 FORM 4 SUBMISSION 0000899243-22-002646 5418
2021-12-27 4 FORM 4 SUBMISSION 0000899243-21-049764 7196
2021-12-02 8-K 8-K 1.01,2.03,9.01 0000950170-21-004987 001-40603 211464955 34 1154125 1 1
2021-11-10 10-Q 10-Q 0000950170-21-003918 001-40603 211394414 34 6871851 1 1
2021-11-10 8-K 8-K 2.02,9.01 0000950170-21-003893 001-40603 211394347 34 384770 1 1
2021-09-27 4 FORM 4 SUBMISSION 0000899243-21-037802 5055
2021-09-22 4 FORM 4 SUBMISSION 0000899243-21-037149 5060
2021-09-22 4 FORM 4 SUBMISSION 0000899243-21-037147 6584
2021-09-13 4 FORM 4 SUBMISSION 0000899243-21-035684 5059
2021-09-09 4 FORM 4 SUBMISSION 0000899243-21-035470 5459
2021-09-09 3 FORM 3 SUBMISSION 0000899243-21-035469 2905
2021-09-09 4 FORM 4 SUBMISSION 0000899243-21-035442 5081
2021-08-31 4 FORM 4 SUBMISSION 0000899243-21-034610 5064
2021-08-19 10-Q 10-Q 0001564590-21-045079 001-40603 211188397 34 6834226 1 1
2021-08-19 8-K 8-K 2.02,9.01 0001564590-21-045076 001-40603 211188388 34 266167
2021-07-28 SC 13G SC 13G 0001104659-21-096975 005-92700 211122890 34 84104
2021-07-22 4 FORM 4 SUBMISSION 0000899243-21-029479 16100
2021-07-22 SC 13D SC 13D 0001104659-21-094915 005-92700 211107845 34 145843
2021-07-22 4 PRIMARY DOCUMENT 0001638599-21-000606 31448
2021-07-22 4 FORM 4 SUBMISSION 0000899243-21-029440 7000
2021-07-22 4 FORM 4 SUBMISSION 0000899243-21-029437 4652
2021-07-20 8-K 8-K 5.02,5.03,9.01 0001193125-21-219696 001-40603 211101548 34 217843
2021-07-19 424B4 424B4 0001193125-21-218024 333-255491 211096838 33 7561934
2021-07-16 4 FORM 4 SUBMISSION 0000899243-21-028652 5703
2021-07-16 4 FORM 4 SUBMISSION 0000899243-21-028648 7661
2021-07-16 S-8 S-8 0001193125-21-216925 333-257941 211094256 33 218469
2021-07-16 FWP FWP 0001193125-21-216710 333-255491 211093918 34 9752
2021-07-15 EFFECT xslEFFECTX01/primary_doc.xml S-1,,2021-07-15 16:00:00 9999999995-21-002781 333-255491 211094196 33 1681
2021-07-15 S-1MEF S-1MEF 0001193125-21-216744 333-257938 211094159 33 55551
2021-07-15 3 FORM 3 SUBMISSION 0000899243-21-028526 8668
2021-07-15 3 FORM 3 SUBMISSION 0000899243-21-028525 4256
2021-07-15 3 FORM 3 SUBMISSION 0000899243-21-028523 2841
2021-07-15 3 FORM 3 SUBMISSION 0000899243-21-028522 6679
2021-07-15 3 FORM 3 SUBMISSION 0000899243-21-028519 9097
2021-07-15 3 FORM 3 SUBMISSION 0000899243-21-028517 4243
2021-07-15 3 FORM 3 SUBMISSION 0000899243-21-028516 7639
2021-07-15 3 FORM 3 SUBMISSION 0000899243-21-028513 2832
2021-07-15 3 FORM 3 SUBMISSION 0000899243-21-028512 4165
2021-07-15 3 PRIMARY DOCUMENT 0001638599-21-000603 18117
2021-07-15 3 PRIMARY DOCUMENT 0001638599-21-000602 2849
2021-07-15 SEC STAFF LETTER filename1.pdf 9999999997-21-004135 271769
2021-07-15 CERT 8A_Cert_TCRX.pdf 0001354457-21-000796 001-40603 211091975 34 583035
2021-07-14 CORRESP filename1.htm 0001193125-21-215243 19820
2021-07-13 UPLOAD filename1.pdf 0000000000-21-008658 44018
2021-07-13 8-A12B 8-A12B 0001193125-21-214090 001-40603 211087937 34 14011
2021-07-13 CORRESP filename1.htm 0001193125-21-213952 10384
2021-07-13 CORRESP filename1.htm 0001193125-21-213949 10002
2021-07-12 S-1/A S-1/A 0001193125-21-212364 333-255491 211084189 33 7425919
2021-05-14 S-1/A S-1/A 0001193125-21-161996 333-255491 21924561 33 7439730
2021-05-05 CORRESP filename1.htm 0001193125-21-151730 17946
2021-05-05 S-1/A S-1/A 0001193125-21-151721 333-255491 21893372 33 248628
2021-05-03 UPLOAD filename1.pdf 0000000000-21-005643 44672
2021-04-30 CORRESP filename1.htm 0001193125-21-145468 31216
2021-04-30 S-1/A S-1/A 0001193125-21-145429 333-255491 21879314 33 7260325
2021-04-30 CORRESP filename1.htm 0001193125-21-143774 108963
2021-04-29 UPLOAD filename1.pdf 0000000000-21-005435 49961
2021-04-28 SEC STAFF LETTER filename1.pdf 9999999997-21-002242 272404
2021-04-23 CORRESP filename1.htm 0001193125-21-129279 72347
2021-04-23 S-1 S-1 0001193125-21-129264 333-255491 21850659 33 10025039
2021-04-15 UPLOAD filename1.pdf 0000000000-21-004581 69832
2021-04-12 SEC STAFF LETTER filename1.pdf 9999999997-21-001727 276699
2021-03-19 DRS filename1.htm 0000950123-21-003678 377-04469 21759163 33 7414462
2021-01-28 D xslFormDX01/primary_doc.xml 06b 0001783328-21-000001 021-387638 21562362 33 11671
2019-07-26 D xslFormDX01/primary_doc.xml 06b 0001783328-19-000001 021-345133 19976745 33 11796

Latest XBRL company facts

One latest value per concept from companyfacts (190 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 23.98M 2022-03-04 2021 FY 10-K 2022-03-09 0000950170-22-003175
dei EntityPublicFloat Entity Public Float USD 56.87M 2025-06-30 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 1.24M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap AccountsReceivableNetCurrent Accounts Receivable, after Allowance for Credit Loss, Current USD 31.93M 2023-06-30 2023 Q2 10-Q 2023-08-10 0000950170-23-040961
us-gaap AccruedLiabilitiesAndOtherLiabilities Accrued Liabilities and Other Liabilities USD 12.88M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap AccruedProfessionalFeesCurrent Accrued Professional Fees, Current USD 765,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 21.57M 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD 51,000 2024-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap AdditionalPaidInCapitalCommonStock Additional Paid in Capital, Common Stock USD 634.98M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt USD 14.75M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 2.08M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap AdjustmentsToAdditionalPaidInCapitalWarrantIssued Adjustments to Additional Paid in Capital, Warrant Issued USD 158.07M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 11.71M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 19.58M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap Assets Assets USD 141.40M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap AssetsCurrent Assets, Current USD 76.78M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap AssetsFairValueDisclosure Assets, Fair Value Disclosure USD 68.86M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap CapitalExpendituresIncurredButNotYetPaid Capital Expenditures Incurred but Not yet Paid USD 52,000 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 73.04M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 78.07M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD -79.37M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance shares 92.65M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0 2021-06-30 2021 Q2 10-Q 2021-08-19 0001564590-21-045079
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 165.21M 2021-06-30 2021 Q2 10-Q 2021-08-19 0001564590-21-045079
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 1.68M 2021-06-30 2021 Q2 10-Q 2021-08-19 0001564590-21-045079
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 1.42M 2021-06-30 2021 Q2 10-Q 2021-08-19 0001564590-21-045079
us-gaap CommonStockValue Common Stock, Value, Issued USD 1,000 2021-06-30 2021 Q2 10-Q 2021-08-19 0001564590-21-045079
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -92.11M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap ConversionOfStockAmountConverted1 Conversion of Stock, Amount Converted USD 14.75M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap ConvertiblePreferredStockSharesIssuedUponConversion Convertible Preferred Stock, Shares Issued upon Conversion shares 7.06M 2020-12-31 2021 FY 10-K 2022-03-09 0000950170-22-003175
us-gaap DebtInstrumentCarryingAmount Long-term Debt, Gross USD 34.13M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap DebtInstrumentInterestRateDuringPeriod Debt Instrument, Interest Rate During Period pure 0.126 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-12 0000950170-24-124575
us-gaap DebtInstrumentUnamortizedDiscount Debt Instrument, Unamortized Discount USD 1.15M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction USD 400,000 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap DeferredCosts Deferred Costs, Noncurrent USD 2.54M 2021-06-30 2021 Q2 10-Q 2021-08-19 0001564590-21-045079
us-gaap DeferredCostsCurrent Deferred Costs, Current USD 2.50M 2021-06-30 2021 Q2 10-Q 2021-08-19 0001564590-21-045079
us-gaap DeferredRevenueCurrent Deferred Revenue, Current USD 2.62M 2025-12-31 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap DeferredRevenueNoncurrent Deferred Revenue, Noncurrent USD 1.25M 2024-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap DeferredTaxAssetsDeferredIncome Deferred Tax Assets, Deferred Income USD 716,000 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance USD 177.03M 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 48.48M 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap DeferredTaxAssetsOther Deferred Tax Assets, Other USD 13.18M 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap DeferredTaxAssetsTaxCreditCarryforwards Deferred Tax Assets, Tax Credit Carryforwards USD 32.10M 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 2.32M 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 161.26M 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap DefinedContributionPlanEmployerDiscretionaryContributionAmount Defined Contribution Plan, Employer Discretionary Contribution Amount USD 1.30M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap DepositsAssetsNoncurrent Deposits Assets, Noncurrent USD 75,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap Depreciation Depreciation USD 2.07M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap DepreciationAndAmortization Depreciation, Depletion and Amortization, Nonproduction USD 2.90M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -0.71 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -0.67 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-12 0000950170-22-009472
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -0.71 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.225 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure -0.017 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent pure -0.009 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure 0.075 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap EffectiveIncomeTaxRateReconciliationTaxCredits Effective Income Tax Rate Reconciliation, Tax Credit, Percent pure 0.05 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent pure 0.03 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap EmployeeRelatedLiabilitiesCurrent Employee-related Liabilities, Current USD 6.99M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount USD 18.80M 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap FairValueAssetsLevel1ToLevel2TransfersAmount Fair Value, Assets, Level 1 to Level 2 Transfers, Amount USD 0 2022-03-31 2022 Q1 10-Q 2022-05-12 0000950170-22-009472
us-gaap FairValueAssetsLevel2ToLevel1TransfersAmount Fair Value, Assets, Level 2 to Level 1 Transfers, Amount USD 0 2022-03-31 2022 Q1 10-Q 2022-05-12 0000950170-22-009472
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap GainLossOnSaleOfPropertyPlantEquipment Gain (Loss) on Disposition of Property Plant Equipment USD -99,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap GainsLossesOnExtinguishmentOfDebt Gain (Loss) on Extinguishment of Debt USD -1.09M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 24.68M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 29.13M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -27.23M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap IncomeTaxReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount USD 19,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap IncomeTaxReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount USD 3.90M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD 4,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap IncreaseDecreaseInAccountsReceivable Increase (Decrease) in Accounts Receivable USD 31.93M 2023-01-01 2023-06-30 2024 Q2 10-Q 2024-08-12 0000950170-24-095066
us-gaap IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities USD 5.21M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap IncreaseDecreaseInContractWithCustomerLiability Increase (Decrease) in Contract with Customer, Liability USD -2.62M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap IncreaseDecreaseInOperatingLeaseLiability IncreaseDecreaseInOperatingLeaseLiability USD 38,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD -1.08M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap IncreaseDecreaseInPrepaidRent Increase (Decrease) in Prepaid Rent USD 2.17M 2022-01-01 2022-09-30 2023 Q3 10-Q 2023-11-09 0000950170-23-061533
us-gaap InterestAndOtherIncome Interest and Other Income USD 2.72M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap InterestExpense Interest Expense USD 2.16M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap InterestExpenseLongTermDebt Interest Expense, Long-term Debt USD 2.90M 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-12 0000950170-24-124575
us-gaap InterestIncomeOther Interest Income, Other USD 11,000 2021-01-01 2021-06-30 2021 Q2 10-Q 2021-08-19 0001564590-21-045079
us-gaap InterestPaidNet Interest Paid, Excluding Capitalized Interest, Operating Activities USD 1.73M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap InterestPayableCurrent Interest Payable, Current USD 190,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap LeaseCost Lease, Cost USD 18.64M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap LesseeOperatingLeaseDiscountRate Lessee, Operating Lease, Discount Rate pure 0.099 2022-10-28 2022 FY 10-K 2023-03-08 0000950170-23-006589
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 83.99M 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 12.96M 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFive Lessee, Operating Lease, Liability, to be Paid, Year Five USD 184,000 2021-12-31 2021 FY 10-K 2022-03-09 0000950170-22-003175
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 13.35M 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 13.71M 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 13.33M 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 22.39M 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap Liabilities Liabilities USD 103.39M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 141.40M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap LiabilitiesCurrent Liabilities, Current USD 37.82M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap LongTermDebt Long-term Debt USD 32.97M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap LongTermDebtCurrent Long-term Debt, Current Maturities USD 15.70M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Long-Term Debt, Maturity, Year One USD 16.25M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive Long-Term Debt, Maturity, Year Five USD 12.19M 2025-09-30 2025 Q3 10-Q 2025-11-12 0001193125-25-275933
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour Long-Term Debt, Maturity, Year Four USD 12.19M 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree Long-Term Debt, Maturity, Year Three USD 12.19M 2026-03-31 2026 Q1 10-Q 2026-05-06 0001193125-26-207572
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Long-Term Debt, Maturity, Year Two USD 13.81M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear Long-Term Debt, Maturity, Remainder of Fiscal Year USD 4.06M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap LongTermDebtNoncurrent Long-term Debt, Excluding Current Maturities USD 17.27M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap MarketableSecuritiesCurrent Marketable Securities, Current USD 111.42M 2024-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 99,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD -576,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -78.89M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -92.11M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Net Income (Loss) Available to Common Stockholders, Basic USD -47.50M 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-09 0000950170-22-023507
us-gaap NumberOfOperatingSegments Number of Operating Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap NumberOfReportableSegments Number of Reportable Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap OperatingExpenses Operating Expenses USD 95.28M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -92.66M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap OperatingLeaseCost Operating Lease, Cost USD 13.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 61.60M 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 8.00M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 48.30M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap OperatingLeasePayments Operating Lease, Payments USD 10.10M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 52.41M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.08 2021-12-31 2021 FY 10-K 2022-03-09 0000950170-22-003175
us-gaap OperatingLossCarryforwards Operating Loss Carryforwards USD 174.70M 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 190,000 2026-06-30 2026 Q2 10-Q 2026-08-12 0001193125-26-345749
us-gaap OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap OtherLiabilitiesNoncurrent Other Liabilities, Noncurrent USD 135,000 2024-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap OtherNonoperatingIncomeExpense Other Nonoperating Income (Expense) USD 553,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap PaymentsForRestructuring Payments for Restructuring USD 2.37M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap PaymentsForTenantImprovements Payments for Tenant Improvements USD 3.80M 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-09 0000950170-22-023507
us-gaap PaymentsOfDebtIssuanceCosts Payments of Debt Issuance Costs USD 324,000 2022-01-01 2022-12-31 2023 FY 10-K 2024-03-06 0000950170-24-026875
us-gaap PaymentsOfFinancingCosts Payments of Financing Costs USD 200,000 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap PaymentsToAcquireMarketableSecurities Payments to Acquire Marketable Securities USD 87.47M 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 604,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 10.00M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap PreferredStockValue Preferred Stock, Value, Issued USD 0 2025-09-30 2025 Q3 10-Q 2025-11-12 0001193125-25-275933
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 3.75M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap PrepaidExpenseNoncurrent Prepaid Expense, Noncurrent USD 3.76M 2022-09-30 2022 Q3 10-Q 2022-11-09 0000950170-22-023507
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 89.65M 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-08 0000950170-23-006589
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 33.10M 2024-04-24 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap ProceedsFromIssuanceOfConvertiblePreferredStock Proceeds from Issuance of Convertible Preferred Stock USD 99.73M 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-08 0000950170-23-006589
us-gaap ProceedsFromIssuanceOfLongTermDebt Proceeds from Issuance of Long-term Debt USD 29.35M 2022-01-01 2022-12-31 2023 FY 10-K 2024-03-06 0000950170-24-026875
us-gaap ProceedsFromIssuanceOfWarrants Proceeds from Issuance of Warrants USD 29.80M 2024-12-27 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap ProceedsFromLinesOfCredit Proceeds from Lines of Credit USD 32.46M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap ProceedsFromSaleAndMaturityOfMarketableSecurities Proceeds from Sale and Maturity of Marketable Securities USD 186.25M 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap ProceedsFromSaleOfPropertyPlantAndEquipment Proceeds from Sale of Property, Plant, and Equipment USD 28,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 1.72M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap ProceedsFromStockPlans Proceeds from Stock Plans USD 99,000 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-12 0001193125-26-345749
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -92.11M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 30.28M 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 7.11M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap RepaymentsOfNotesPayable Repayments of Notes Payable USD 17.14M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 70.60M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap RestrictedCashNoncurrent Restricted Cash, Noncurrent USD 5.03M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap RestructuringAndRelatedCostNumberOfPositionsEliminated Restructuring and Related Cost, Number of Positions Eliminated Role 66 2025-11-03 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent Restructuring and Related Cost, Number of Positions Eliminated, Period Percent pure 0.75 2026-09-02 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap RestructuringReserve Restructuring Reserve USD 3.07M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -596.97M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap RevenueFromContractWithCustomerExcludingAssessedTax Revenue from Contract with Customer, Excluding Assessed Tax USD 2.62M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 6.13M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap SeveranceCosts1 Severance Costs USD 4.42M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 6.90M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate pure 0.96 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate pure 0.044 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value USD 1.95M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 2.19 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap ShortTermLeaseCost Short-term Lease, Cost USD 44,000 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-05 0000950170-25-033077
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 38.01M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio pure 8.2 2021-05-13 2021 Q3 10-Q 2021-11-10 0000950170-21-003918
us-gaap StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Stock Issued During Period, Value, Employee Stock Purchase Plan USD 99,000 2026-04-01 2026-06-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 33.13M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 1.72M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap TemporaryEquityCarryingAmountAttributableToParent Temporary Equity, Carrying Amount, Attributable to Parent USD 59.68M 2020-12-31 2021 FY 10-K 2022-03-09 0000950170-22-003175
us-gaap TemporaryEquityLiquidationPreference Temporary Equity, Liquidation Preference USD 68.88M 2020-12-31 2021 FY 10-K 2022-03-09 0000950170-22-003175
us-gaap TemporaryEquitySharesAuthorized Temporary Equity, Shares Authorized shares 57.92M 2020-12-31 2021 FY 10-K 2022-03-09 0000950170-22-003175
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 0 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued USD 0 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD 39.70M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap VariableLeaseCost Variable Lease, Cost USD 5.64M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-04 0001193125-26-089884
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 129.96M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 23.97M 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-12 0000950170-22-009472
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 129.96M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-456919

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →